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ABSTRACT
Objectives to validate cut-offs of the Juvenile arthritis 
Disease activity Score 10 (JaDaS10) and clinical JaDaS10 
(cJaDaS10) and to compare them with other patient 
cohorts.
Methods in a national multicentre study, cross-sectional 
data on recent visits of 337 non-systemic patients with 
juvenile idiopathic arthritis (Jia) were collected from nine 
paediatric outpatient units. the cut-offs were tested with 
receiver operating characteristic curve-based methods, 
and too high, too low and correct classification rates 
(ccrs) were calculated.
Results Our earlier presented JaDaS10 cut-offs seemed 
feasible based on the ccrs, but the cut-off values 
between low disease activity (lDa) and moderate disease 
activity (MDa) were adjusted. When JaDaS10 cut-offs for 
clinically inactive disease (ciD) were increased to 1.5 for 
patients with oligoarticular disease and 2.7 for patients 
with polyarticular disease, as recently suggested in a 
large multinational register study, altogether 11 patients 
classified as ciD by the cut-off had one active joint. 
We suggest JaDaS10 cut-off values for oligoarticular/
polyarticular disease to be in ciD: 0.0–0.5/0.0–0.7, lDa: 
0.6–3.8/0.8–5.1 and MDa: >3.8/5.1. Suitable cJaDaS10 
cut-offs are the same as JaDaS10 cut-offs in oligoarticular 
disease. in polyarticular disease, cJaDaS10 cut-offs are 
0–0.7 for ciD, 0.8–5.0 for lDa and >5.0 for MDa.
Conclusion international consensus on JaDaS cut-
off values is needed, and such a cut-off for ciD should 
preferably exclude patients with active joints in the ciD 
group.
InTROduCTIOn
Juvenile idiopathic arthritis (JIA) is a group 
of childhood arthritides in which prolonged 
synovial inflammation can lead to long-term 
consequences, such as growth impairment, 
joint destruction, osteoporosis and chronic 
pain.1 There is growing evidence that early 
aggressive treatment improves the outcome.2–6 
The ultimate treatment goal is clinically inac-
tive disease (CID),7 8 but this is not always 
achievable. There have been attempts to 
divide disease activity into different levels 
based on clinical criteria in order to develop 
tools to establish guidelines for therapeutic 
interventions, to monitor disease status in 
a single patient or different patient groups, 
and to enable comparison in research.9–13 
The Wallace preliminary criteria of CID7 
have further been evolved to the American 
College of Rheumatology (ACR) provisional 
criteria of CID,8 which also include duration 
of morning stiffness. The Wallace preliminary 
definition of CID7 and the ACR provisional 
criteria of CID8 have been used consistently 
in paediatric research, but with some contro-
versy, the literature has shown several clinical 
Key messages
What is already known about this subject?
 ► cut-off values of Juvenile arthritis Disease activity 
Score (JaDaS) and clinical JaDaS are useful tools 
for determining disease activity levels.
What does this study add?
 ► the optimal JaDaS10 cut-off value for remission is 
0.5 in patients with oligoarticular disease and 0.7 in 
patients with polyarticular disease.
 ► these JaDaS10 cut-off values for remission ex-
cludes all patients with active joints.
How might this impact on clinical practice?
 ► JaDaS10 cut-off values allow patients to understand 
the meaning of disease activity by providing com-
prehensible information in the terms: clinically inac-
tive disease, low, moderate and high disease activity.
 ► the feasability of JaDaS10 cut-off values would im-
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definitions for minimal or low disease activity (LDA), 
moderate disease activity (MDA) and high disease activity 
(HDA).9–13 In particular, the definition of HDA differs 
markedly depending on which source is used.10–14
Some of the existing clinical criteria for disease activity 
levels9 10 are time-consuming to interpret, whereas the 
Juvenile Arthritis Disease Activity Score (JADAS)15 and 
especially the clinical JADAS (cJADAS) indexes16 17 are 
more useful in daily practice. The JADAS is a contin-
uous disease activity score specific to JIA and consists of 
four parameters: active joint count (AJC), physician’s 
global assessment of disease activity, parent/patient 
evaluation of the child’s overall well-being and erythro-
cyte sedimentation rate (ESR).15 The cJADAS is JADAS 
excluding ESR.16 These JADAS indexes create consis-
tency in disease activity evaluation between physicians 
and allow patients to understand the meaning of disease 
activity by providing a single score number. Nevertheless, 
to assess the meaning of a single JADAS score might be 
cumbersome. Thus, cut-off values of JADAS,12 13 18–20 and 
cJADAS,13 17 19 20 have been established for disease activity 
levels. Some variation exists in the proposed cut-off 
values since different references have been used.9 11 12 15 17 
Especially the latest proposed cut-offs by Consolaro et al 
are higher than the earlier ones and in their work expert 
subject opinions are used as reference.19 Consensus on 
which of these cut-off values to use does not yet exist.
Recently, we established the JADAS10 and cJADAS10 
intervals for the Wallace preliminary criteria of CID7 and 
LDA and MDA according to Beukelman et al10 20 and 
HDA according to Backström et al.13 These JADAS10 
cut-off values needed validation.
Aim
The aim was to validate the previously established 
JADAS10 and cJADAS10 cut-off values13 20 and compare 
them with the cut-off values suggested by Consolaro et 
al.12 17–19
MeTHOds
Patients and statistics with statistical analyses
In Finland, nine paediatric clinics treating patients with 
JIA participated in the study. Patients with systemic JIA 
were excluded. To validate the JADAS10 and cJADAS10 
cut-off levels for LDA and MDA, we used a cross-sectional 
method to retrospectively collect data from the most 
recent visit of all patients with non-systemic JIA seen 
during the period February 2014 to February 2016. The 
most recent visit of all patients resulted in a mixture of 
patients with varying disease activity and duration. In this 
way, the population consisted both of newly diagnosed 
and newly relapsed patients as well as patients who had 
been treated for several years. The population in our 
work defining CID, LDA and MDA cut-offs20 is completely 
different from the one in the present work. Regarding 
the HDA cut-offs 13 out of 14 patients with HDA in the 
present work are also contributing in the work where we 
define clinical criteria for HDA.13 In the work defining 
clinical criteria for HDA, we used the patient’s first visit13 
and in this work we used the patient’s most recent visit.
Data were obtained on age, gender, category of JIA, 
AJC, ESR, physician’s global assessment of disease activity 
using a 10 cm linear visual analogue scale (VAS), parent/
patient global assessment of well-being using a 10 cm 
linear VAS, and the results of rheumatoid factor levels, 
duration of disease and the state of uveitis (the number 
of cells measured in the worse eye during the most 
recent slit lamp examination). Additionally, data on the 
initiation of synthetic or biological disease-modifying 
anti-rheumatic drugs and both systemic and intra-artic-
ular corticosteroids at this visit were recorded. At the 
time point for collection of the data, the co-authors from 
the contributing medical centres had access to all patient 
data from time of diagnosis onward. The co-authors were 
asked to assign the patients to either an oligoarticular or 
polyarticular disease course based on their whole medical 
history of affected joints (≤4 or>4, respectively). We 
reported JADAS10 scores due to the fact that JADAS27 
excludes clinically significant joints (eg, midtarsal and 
temporomandibular joints) and with JADAS10 the AJC 
will have the same weight as physician’s global assessment 
of disease activity, parent/patient global assessment of 
well-being and ESR.
We divided patients into four groups based on disease 
activity levels: CID according to the Wallace preliminary 
criteria,7 LDA and MDA according to Beukelman et al,10 
and HDA according to Backström et al.13 At the time we 
started our first study on JADAS cut-off values in January 
2013, no other clinical definition for MDA or HDA 
existed but the Beukelman’s definition.10 That is why 
we chose to use the Beukelman’s definition of disease 
activity levels and not the one by Magni-Manzoni et al.9 
CID was defined according to the Wallace preliminary 
criteria7 because the duration of morning stiffness was 
unknown. We then validated the previously determined 
JADAS10 and cJADAS10 cut-off values13 19 and compared 
our cut-offs to those suggested by Consolaro et al.12 17–19
statistics
Originally, data from 384 patients were collected. 
Complete data of the core set variables were available 
from 337 of 384 patients. Those patients with incom-
plete data of the core set variables were excluded from 
the analysis of validation. The differences in the core set 
criteria of JADAS between the patients with a complete 
data set and those with some core set criteria missing 
were compared using the Mann-Whitney U test. This test 
was used due to the skewed distributions.
In the patients with complete data set, we determined 
JADAS10 and cJADAS10 cut-off values for the Wallace 
preliminary criteria of CID,7 LDA and MDA according 
to Beukelman et al,10 and HDA according to Backström 
et al13 using three different receiver operating charac-
teristics curve (ROC)-based methods: the one closest 
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Table 1 Clinical characteristics in a Finnish cohort of 337 
patients with non-systemic JIA
Females, n (%) 209 (62.0)
Age in years, median (range) 9.8 (1.9–18.0)
Disease duration in years, median (range) 2 (0–7)
Categories of JIA
  Oligoarthritis, persistent, n (%) 155 (46.0)
  Oligoarthritis, extended, n (%) 9 (2.7)
  Polyarthritis, RF negative, n (%) 124 (36.8)
  Polyarthritis, RF positive, n (%) 16 (4.7)
  Enthesitis-related arthritis, n (%) 12 (3.6)
  Psoriatic arthritis, n (%) 9 (2.7)
  Undifferentiated arthritis, n (%) 4 (1.2)
Physician’s global assessment of disease activity in cm, 
median (IQR)
0.0 (0–1.2)
Parent/patient global assessment of well-being in cm, 
median (IQR)
0.5 (0–2.2)
Number of joints with active arthritis, median (IQR) 0 (0–1)
ESR in mm/h, median (IQR) 5 (2–8)
JADAS, median (IQR) 1.7 (0–4.5)
cJADAS, median (IQR) 1.6 (0–4.4)
ESR, erythrocyte sedimentation rate; JADAS, Juvenile Arthritis Disease Activity Score; 
JIA, juvenile idiopathic arthritis; RF, rheumatoid factor; cJADAS, clinical JADAS.
highest degree of combined sensitivity and specificity, 
and the 75th centile. The area under the ROC curve was 
determined. The cut-off values were further validated by 
counting the correct classification rate (CCR) and the 
too high and too low classification rates of the values.
Analyses were performed using SPSS Statistics, V.20 
(IBM, Armonk, NY, USA) and SAS System for Windows, 
V.9.4 (SAS Institute, Cary, NC, USA).
ethics
The study complies with the Declaration of Helsinki. 
The retrospective data were gathered without patient 
identification. Based on the Finnish ethical regulations, 
no patient consent or ethical committee approval was 
needed. Instead, permission was obtained from the head 
physicians of the hospitals participating in this study.
ResulTs
For the validation of earlier JADAS10 cut-off values,20 384 
registered most recent outpatient visits were reported. 
The earlier cut-off values are in oligoarticular/polyar-
ticular disease as following; CID: 0–0.5/0.0–0.7, LDA: 
0.6–2.7/0.8–3.9, MDA: 2.8–6.6/4.0–15.2 and HDA: 
≥6.7/15.3. The cJADAS10 cut-off values are the same as 
JADAS10 cut-off-values except for HDA in polyarticular 
disease that is ≥14.1.13 20 Of the 337 patients with complete 
data, the median age was 9.8 (range 1.9–18.0) years, and 
209 (62.0%) were girls (table 1). According to the Wallace 
preliminary criteria,7 158 (46.9%) were classified as CID, 
and according to Beukelman et al,10 76 (22.6%) were 
classified as LDA, 102 (30.3%) as MDA and 1 (0.3%) as 
HDA. Using the HDA definition proposed by Backström 
et al,13 89 (26.4%) patients were classified as MDA and 14 
(4.2%) as HDA. At the most recent visit, oligoarticular 
disease course was detected in 183 patients (54.3%) and 
polyarticular course in 154 (45.7%). In those with some 
core set criteria of JADAS missing (n=47), the data on 
AJC were missing in two patients, ESR in 22 patients, 
physician’s VAS in 26 patients and parent/patient VAS in 
36 patients. Those with some core set criteria of JADAS 
missing had slightly more active joints (median 1 vs 0, 
p=0.02), had shorter disease duration (median 0.84 vs 
1.44 years, p<0.0001) and were younger (median 5.9 vs 
9.8 years, p=0.002) at the last recorded visit than those 
with a complete data set. Between groups with all versus 
some missing data, no difference was observed in ESR, 
physician’s VAS or parent/patient VAS.
The JADAS10 and cJADAS10 cut-off values obtained 
through all the used ROC-based methods (table 2) 
were rather close to cut-off values we wanted to vali-
date.13 20 Raising the JADAS10 cut-off value between CID 
and LDA to 1.0 in both oligoarthritis and polyarthritis, as 
suggested by Consolaro et al,18 lowered the CCR of LDA 
and led to an increase in the number of patients with 
LDA classified as having CID (table 3). Three of the 12 
patients with oligoarticular disease whose JADAS10 was 
0.6–1.0 were misclassified as having CID although they 
had LDA. This was due to one active joint in one patient 
and a physician’s VAS score of 1 in two patients. Four of 
the 12 patients with polyarticular disease with JADAS10 
of 0.8–1.0 were misclassified as having CID although they 
had LDA. This was due to a physician’s VAS score of 1 in 
three patients and an ESR elevation of 22 in one patient.
When the JADAS10 cut-off value for CID was raised 
according to the newest proposal of 1.5 for patients with 
oligoarticular disease and 2.6 for patients with polyar-
ticular disease,19 179 patients (53.1%) were classified as 
being in remission (table 3), and 11 of these 179 patients 
(6.1%) had one active joint.
When using the cut-off value for CID of 0.5 for patients 
with oligoarticular disease and 0.7 for patients with poly-
articular disease none of the patients classified as being 
in remission had any active joints (table 4).
In patients with oligoarticular disease, the CCR for 
LDA based on our earlier cut-off values20 was 41.9% 
(table 3). According to clinical criteria,10 as many as 
35.0% of patients with LDA were classified as having 
CID. They were misclassified due to active uveitis and an 
only slightly elevated physician’s VAS score (0.1–0.5). On 
the other hand, 25.6% of all patients with oligoarticular 
disease with CID, according to the Wallace preliminary 
criteria,7 had JADAS10 scores corresponding to LDA or 
MDA due to high parent/patient VAS in patients with no 
evident signs of clinical arthritis. The JADAS10 range for 
LDA derived through the Youden21 method (JADAS10 
0.4–3.8 in oligoarthritis and 0.7–5.1 in polyarthritis) had 
the best CCRs for LDA, which were 83.7% in oligoar-
thritis and 81.8% in polyarthritis. Raising our cut-off 
values between LDA and MDA to 3.8 in oligoarthritis and 
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Table 2 The CCR, too low and too high classification rate of JADAS10 and cJADAS10 cut-off values for selected disease 
activity levels of JIA, CID according to Wallace,7 LDA and MDA as proposed by Beukelman et al10 and HDA as proposed by 
Backström et al13 using three different receiver operating characteristic curve-based methods: the one closest to point (0.1), 
the Youden index21 and the 75th centile
Cut-off range CCR (%) Too low (%) Too high (%)
JADAS10 cJADAS10 JADAS10 cJADAS10 JADAS10 cJADAS10 JADAS10 cJADAS10
Oligoarticular disease
CID7 (n=86)
  Closest to point ≤0.5 ≤0.5 74.4 74.4 – – 25.6 25.6
  Youden index ≤0.3 ≤0.3 68.6 68.6 – – 31.4 31.4
  75th centile ≤0.6 ≤0.6 76.7 76.7 – – 23.3 23.3
LDA10 (n=43)
  Closest to point 0.6–3.6 0.6–3.6 62.8 62.8 27.9 27.9 9.3 9.3
  Youden index 0.4–3.8 0.4–3.8 83.7 83.7 11.6 11.6 4.7 4.7
  75th centile 0.7–2.8 0.7–2.8 48.8 48.8 27.9 27.9 23.3 23.3
MDA10 (n=46)
  Closest to point 3.7–7.8 3.7–7.8 67.4 65.2 19.6 21.7 13.0 13.1
  Youden index 3.9–7.8 3.9–7.8 59.0 59.0 28.0 28.0 13.0 13.0
  75th centile 2.9–6.7 2.9–6.7 65.2 63.0 10.9 13.0 23.9 24.0
HDA13 (n=8)
  Closest to point ≥7.9 ≥7.9 62.5 62.5 37.5 37.5 – –
  Youden index ≥7.9 ≥7.9 62.5 62.5 37.5 37.5 – –
  75th centile ≥6.8 ≥6.8 75.0 75.0 25.0 25.0 – –
Average CCR of all disease 
activity levels (n=154)
  Closest to point 66.8 66.3
  Youden index 68.4 68.4
  75th centile 66.4 65.9
Polyarticular disease
CID7 (n=72)
  Closest to point ≤1.2 ≤1.2 76.4 76.4 – – 23.6 23.6
  Youden index ≤0.7 ≤0.7 65.3 65.3 – – 34.7 34.7
  75th centile ≤1.0 ≤1.0 76.4 76.4 – – 23.6 23.6
LDA10 (n=33)
  Closest to point 1.3–5.0 1.3–4.8 69.7 66.7 24.2 24.2 6.1 9.1
  Youden index 0.8–5.1 0.8–5.0 81.8 81.8 12.1 12.1 6.1 6.1
  75th centile 1.0–3.8 1.0–3.8 54.5 54.5 21.2 21.2 24.3 24.3
MDA10 (n=43)
  Closest to point 5.1–16.0 4.9–16.0 72.0 74.4 23.3 23.3 4.7 2.3
  Youden index 5.2–16.0 5.1–16.0 69.7 69.8 25.6 27.9 4.7 2.3
  75th centile 3.9–11.0 3.9–11.0 55.8 55.8 20.9 20.9 23.3 23.3
HDA13 n=6
  Closest to point ≥16.0 ≥16.0 83.3 83.3 16.7 16.7 – –
  Youden index ≥16.0 ≥16.0 83.3 83.3 16.7 16.7 – –
  75th centile ≥11.0 ≥11.0 100.0 100.0 0.0 0.0 – –
Average CCR of all disease 
activity levels (n=154)
  Closest to point 75.4 75.2
  Youden index 75.0 75.1
  75th centile 71.7 71.7
CCR, correct classification rate; CID, clinically inactive disease; HDA, high disease activity; JADAS, Juvenile Arthritis Disease Activity Score; JIA, juvenile idiopathic arthritis; LDA, low 
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Table 3 CCR, too low and too high classification rate (%) and average CCR of JADAS10 and cJADAS10 cut-off values 
proposed by Backström et al13 20 and by Consolaro et al12 17–19 for selected disease activity levels of JIA; CID according to 
Wallace,7 LDA and MDA as proposed by Beukelman et al10 and HDA as proposed by Backström et al13
Cut-off range CCR (%) Too low (%) Too high (%)




  Backström et al20 0.5 0.5 74.4 74.4 – – 25.6 25.6
  Consolaro et 
al17 18
1.0 1.0 84.9 84.8 – – 15.1 15.1
  Consolaro et al19 1.5 1.2 90.7 84.9 – – 9.3 15.1
LDA10
  Backström et al20 0.6–2.7 0.6–2.7 41.9 41.9 27.9 27.9 30.2 30.2
  Consolaro et 
al17 18
1.1–2.0 1.1–1.5 23.2 11.6 34.9 34.9 41.9 53.5
  Consolaro et al19 1.6–3.9 1.3–3.4 48.8 48.8 46.5 37.2 4.6 14.0
MDA10
  Backström et 
al13 20
2.8–6.6 2.8–6.6 65.2 60.9 9.7 13.0 26.1 26.1
  Consolaro et al12 
17 18
2.1–4.2 1.6–4.0 32.6 32.6 2.2 2.2 65.2 65.2
  Consolaro et al19 4.0–16.4 3.5–14.3 71.7 78.3 28.3 19.6 0.0 2.2
HDA13
  Backström et al13 >6.6 >6.6 75.0 75.0 25.0 24.0 – –
  Consolaro et 
al12 18
>4.2 >4.0 100.0 87.5 0 12.5 – –
  Consolaro et al19 >16.4 >14.3 0.0 0.0 100.0 100.0 – –
Average CCR of 
all disease activity 
levels
  Backström et 
al13 20
64.1 63.1
  Consolaro et al12 
17 18
60.2 54.1




  Backström et al20 0.7 0.7 65.3 65.3 – – 34.7 34.7
  Consolaro et 
al17 18
1.0 1.0 76.4 76.4 – – 23.6 23.6
  Consolaro et al19 2.6 2.4 90.3 86.1 – – 9.7 13.9
LDA10
  Backström et al20 0.8–3.9 0.8–3.9 63.6 63.6 12.1 12.1 24.2 24.2
  Consolaro et 
al17 18
1.1–3.8 1.1–2.5 54.5 30.3 21.5 21.2 24.2 48.5
  Consolaro et al19 2.7–5.1 2.5–5.1 39.4 42.4 54.5 51.5 6.1 6.1
MDA10
  Backström et 
al13 20
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Cut-off range CCR (%) Too low (%) Too high (%)
JADAS10 cJADAS10 JADAS10 cJADAS10 JADAS10 cJADAS10 JADAS10 cJADAS10
  Consolaro et al12 
17 18
3.9–10.5 2.6–8.5 53.4 44.2 21.0 11.6 25.6 44.2
  Consolaro et al19 5.2–18.9 5.1–19.0 74.4 72.1 25.6 27.9 0.0 0.0
HDA13
  Backström et al13 >15.2 >14.0 100.0 100.0 0.0 0.0 – –
  Consolaro et 
al12 18
>10.5 >8.5 100.0 100.0 0.0 0.0 – –
  Consolaro et al19 >18.9 >19.0 83.3 50.0 16.7 50.0 – –
Average CCR of 
all disease activity 
levels n=154
  Backström et 
al13 20
74.7 74.7
  Consolaro et 
al17 18
71.1 62.7
  Consolaro et al19 71.9 62.7
CCR, correct classification rate; CID, clinically inactive disease; HDA, high disease activity; JADAS, Juvenile Arthritis Disease Activity Score; 
JIA, juvenile idiopathic arthritis; LDA, low disease activity; MDA, moderate disease activity; cJADAS, clinical JADAS.
Table 3 Continued
and 81.8%, respectively, without a negative impact on the 
average CCR of all activity levels (65.6% in oligoarthritis 
and 78.1% in polyarthritis).
The JADAS10 and cJADAS10 cut-off values for HDA 
in both oligoarticular and polyarticular disease were 
only slightly different from our earlier cut-off values 
(table 2),13 but since only 14 patients were in HDA, this 
result could not be used in the validation
The new proposed and validated JADAS10 cut-off 
values in oligoarticular/polyarticular disease are in 
CID: 0.0–0.5/0.0–0.7, LDA: 0.6–3.8/0.8–5.1 and MDA 
>3.8/5.1. Suitable cJADAS10 cut-offs are the same as 
JADAS10 cut-offs in oligoarticular disease. In polyartic-
ular disease, cJADAS10 cut-offs are 0–0.7 for CID, 0.8–5.0 
for LDA and >5.0 for MDA.
dIsCussIOn
The JADAS10 cut-off values for CID, LDA and MDA 
established earlier20 have now been validated. Based on 
the average CCRs for all disease activity levels, cut-offs 
validated in this study seemed reasonable. The suggested 
JADAS10 cut-offs between CID and LDA in our earlier 
study20 and the present study differ markedly from those 
recently presented by Consolaro et al19 in a large multi-
national study. They proposed JADAS cut-off values 
between CID and LDA that are greater than 1.0, that 
is, 1.5 in oligoarthritis and 2.6 in polyarthritis, although 
these values enable patients with one active joint to be 
classified as in remission. This undermines the use of 
cut-off values as guidance in treatment decisions. When 
the newly proposed JADAS10 cut-off values for remission 
were applied in our population, altogether 11 patients 
with one active joint were classified as in remission.19 
Furthermore, the cut-off value according to Consolaro et 
al19 for CID is markedly higher in polyarthritis than in 
oligoarthritis. We do not think that patients with polyar-
thritis should settle for markedly worse disease activity as 
their treatment target just because they started off with a 
greater number of active joints.
In our data, only 42% of the patients with oligoarticular 
disease with JADAS10 cut-off values of 0.6–2.7 and 64% 
of the patients with polyarticular disease with JADAS10 
cut-off values of 0.8–3.920 were correctly classified as 
having LDA. Thus, our JADAS10 and cJADAS10 cut-off 
values were rather unspecific tools for distinguishing 
patients with oligoarthritis with LDA. One reason for 
this was parent/patient VAS being high in patients with 
no evident signs of clinical arthritis. The Wallace prelim-
inary criteria for CID7 do not include parent/patient 
VAS. A recent study pointed out the importance of the 
definition of CID because only 44% of 633 children with 
CID as defined by the Wallace preliminary criteria or 
JADAS cut-off value had CID according to both criteria.22 
It has also been shown that patients classified as having 
CID according to the Wallace preliminary criteria but 
not by the cJADAS10 cut-off had poorer parent/patient 
reported outcome than those classified as having CID 
according to the cJADAS10 cut-off value.23
In the present study, the scores of parent/patient VAS 
were somewhat higher than those of physician’s VAS. 
The discrepancy between parent/patient and physi-
cian’s VAS has been shown previously.24 When a patient 
or parent has a component of chronic pain in addi-
tion to the burden of JIA, it may result in a high JADAS 
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Table 4 Median of the JADAS10 parameters AJC, physician’s VAS, parent/patient VAS and ESR in patient classified as CID, 
LDA, MDA and HDA according to cut-off values presented in the present study and those proposed earlier by Consolaro et 
al12 18 19
Oligoarticular disease AJC median (range)
Parent/patient VAS 
median (range)
Physician’s VAS median 
(range) ESR median (range)
CID
JADAS10 ≤0.5 (n=77) 0 (0) 0.0 (0.0–0.5) 0.0 (0.0–1.0) 5 (1–20)
JADAS10 ≤1.018 (n=89) 0 (0–1) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 5 (1–20)
JADAS10 ≤1.519 (n=99) 0 (0–1) 0.0 (0.0–1.5) 0.0 (0.0–1.0) 5 (1–20)
LDA
JADAS10 0.6–3.8 (n=60) 0 (0–2) 0.0 (0.0–3.6) 0.5 (0.0–3.0) 4 (2–21)
JADAS10 1.1–2.018 (n=17) 0 (0–1) 1.0 (0.0–2.0) 0.2 (0.0–1.0) 4 (2–11)
JADAS10 1.6–3.919 (n=38) 0 (0–2) 1.5 (0.0–3.6) 0.8 (0.0–3.0) 4 (2–21)
MDA
JADAS10 3.9–6.6 (n=28) 1 (0–3) 2.1 (0.0–5.4) 1.6 (0.0–3.0) 8 (2–31)
JADAS10 2.1–4.218 (n=35) 0 (0–2) 1.6 (0.0–4.0) 1 (0.0–3.0) 4 (2–21)
JADAS10 4.0–16.419 (n=46) 1 (0–3) 3.2 (0.0–10.0) 1.9 (0.0–5.0) 5 (2–31)
HDA
JADAS10 >6.6 (n=18) 1 (0–3) 5.2 (2.6–10.0) 2.0 (1.0–5.0) 4 (2–25)




JADAS10 ≤0.7 (n=52) 0 (0) 0.0 (0.0–0.6) 0.0 (0.0–1.0) 5 (1–18)
JADAS10 ≤1.018 (n=64) 0 (0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 5 (1–22)
JADAS10 ≤2.619 (n=89) 0 (0–1) 0.0 (0.0–2.6) 0.0 (0.0–2.0) 5 (1–33)
LDA
JADAS10 0.8–3.9 (n=60) 0 (0–3) 1.0 (0.0–4.0) 0.5 (0.0–2.0) 5 (1–33)
JADAS10 1.1–3.818 (n=39) 0 (0–2) 1.4 (0.0–3.7) 0.5 (0.0–2.0) 5 (1–33)
JADAS10 2.7–5.119 (n=23) 1 (0–3) 1.7 (0.0–4.4) 1.0 (0.0–2.0) 5 (2–21)
MDA10
JADAS10 4.0–15.2 (n=32) 3 (0–8) 3.8 (0.0–7.8) 2.5 (0.0–4.0) 8 (1–33)
JADAS10 3.9–10.518 (n=34) 2 (0–6) 2.6 (0.0–7.8) 2.0 (0.0–4.0) 7 (1–33)
JADAS10 5.1–18.919 (n=37) 3 (0–10) 4.0 (0.0–8.5) 2.5 (0.0–5.0) 1 (1–44)
HDA13
JADAS10 >15.2 (n=10) 10 (3–15) 4.6 (2.5–8.5) 4.2 (3.0–8.0) 8 (2–62)
JADAS10 >10.512 18 (n=17) 7 (2–15) 4.3 (1.5–8.5) 3.0 (2.0–8.0) 7 (2–62)
JADAS10 >18.919 (n=5) 10 (7–15) 4.3 (2.6–7.6) 6.5 (3.0–8.0) 16 (3–62)
AJC, active joint count; CID, clinically inactive disease; ESR, erythrocyte sedimentation rate; HDA, high disease activity; JADAS, Juvenile Arthritis Disease Activity Score; LDA, low 
disease activity; MDA, moderate disease activity; VAS, visual analogue scale.
objective signs of articular inflammation. Pain is one of 
the parameters that strongly influence a parent’s opinion 
of disease activity.23 In patients with JIA, pain scores asso-
ciate strongly with depression.25 However, it has been 
shown that when restricting the parent/patient VAS from 
cJADAS, identification of patients in need of anti-tumour 
necrosis factor therapy decreases.26 At present, it is not 
possible to distinguish non-inflammatory pain from 
inflammatory pain. Pain scores need to be taken into 
account in the disease state due to the significant impact 
on patients’ well-being. However, our clinical experience 
is that parents who tend to catastrophise27 overestimate 
the disease burden and report a high score on the VAS 
scale regardless of the child’s well-being. We think that 
when analysing patient-reported outcomes, the cata-
strophising tendency of the parent and patient should be 
taken systematically into account by pain catastrophising 
questionnaire.28 This is very important since it would 
raise the chance of optimal intervention for example, 
coaching and supporting when this is needed instead of 
increasing anti-rheumatic medication in the absence of 
signs of inflammation.
Raising the cut-off value for LDA to 1.0 in both 
oligoarthritis and polyarthritis, as previously suggested,18 
further lowered the CCR of LDA. Using that suggestion 
increased the proportion of patients with LDA who were 
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The earlier proposed LDA cut-off for cJADAS17 was 
unsuitable to our population, the CCR being only 
11.4%. One explanation may be normal ESR in 94% 
of cases in the present study. In the present study, the 
Youden method21 had the best performance based on 
the CCR for LDA. Based on this method, the upper 
JADAS10/cJADAS10 limit for LDA would be 3.8/3.8 
for oligoarthritis and 5.1/5.0 for polyarthritis. This 
is in line with the results of the large multinational 
study by Consolaro et al.19 It is probable that these 
are the optimal upper limits for LDA considering the 
average CCR of all disease activity levels in this study. 
The JADAS10 and cJADAS10 cut-off values for HDA in 
this study did not differ much from the cut-off values 
for HDA in our earlier study.13 However, 13 out of 
14 patients with HDA in the present work were also 
contributing in the work where we defined clinical 
criteria for HDA.13 In the work defining clinical criteria 
for HDA, we used the patient’s first visit13 and in this 
work we used the patient’s most recent visit. This clearly 
undermines the reliability and value of the validation of 
the HDA cut-offs. Moreover, in this population, only 14 
patients were in the HDA group, so we do not consider 
the cut-off values between MDA and HDA validated in 
this study. A separate study in is needed to validate the 
cut-off values for HDA.
The discrepancy between the studies seeking to find 
optimal JADAS cut-off values might be due to differences 
in cohorts and statistical methods chosen for the anal-
yses. However, differences may be partly due to various 
definitions of disease activity levels, which are used as a 
reference. In the multinational study by Consolaro et al,19 
the disease activity levels were not set by objective clinical 
criteria; instead, they were established according to the 
subjective opinion of the expert. Likewise, the disease 
activity levels set by Beukelman et al10 are not optimal since 
the HDA definition is set very high, they are not validated 
and they state that with a patient VAS of 2 already has 
MDA even if the physician sees no signs of disease activity. 
However, their strength is that they are objective criteria 
that can be interpreted in approximately the same way 
independent of the physician using them.
In the present study, the median disease duration was 
2 years. Thus, the study population consisted mainly of 
patients in good disease control. A sample of newly diag-
nosed patients would not have been optimal for this vali-
dation study because the number of patients with CID 
would have been small. In order to ascertain an optimal 
variation of disease activity, the best time point for a study 
such as this would be 3–12 months from diagnosis. We 
cannot be sure that these results are relevant outside this 
cohort. Our proposed cut-off values have yet to be tested 
in a large multinational cohort with a greater variation 
in disease activity and where objective reference disease 
activity levels, preferably the same as used in this study, 
can be used as a reference.
In conclusion, we suggest the JADAS10 cut-off values 
to be for oligoarticular/polyarticular disease in CID: 
0.0–0.5/0.0–0.7, LDA: 0.6–3.8/0.8–5.1 and MDA: 
>3.8/5.1. Suitable cJADAS10 cut-offs are the same as 
JADAS10 cut-offs in oligoarticular disease. In polyar-
ticular disease, cJADAS10 cut-offs are 0–0.7 for CID, 
0.8–5.0 for LDA and >5.0 for MDA. It is important to 
reach international consensus on JADAS cut-off values. 
It is preferable to choose a cut-off value for CID that 
excludes patients with active joints from being classi-
fied as having CID based on the JADAS value.
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